| Recovery Guide Intervention for Recurrent Psychiatric Hospitalization (NCT00400166) | Yale University | 2006-12-01 |
| Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder. (NCT00412373) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-12-01 |
| Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder. (NCT00397033) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-11-01 |
| Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone (NCT00406315) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2006-11-01 |
| Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia (NCT00406718) | The University of Texas Health Science Center at San Antonio | 2006-11-01 |
| Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder (NCT00501618) | Manhattan Psychiatric Center | 2006-11-01 |
| Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness (NCT02334228) | Dartmouth-Hitchcock Medical Center | 2006-09-01 |
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness (NCT00661869) | Manhattan Psychiatric Center | 2006-09-01 |
| Long-Acting Injectable Risperidone in the Treatment of Schizophrenia (NCT00132314) | US Department of Veterans Affairs | 2006-09-01 |
| How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs (NCT00514423) | Technical University of Munich | 2006-09-01 |
| Health Evaluation of Abilify Long-term Therapy (NCT00520650) | Taiwan Otsuka Pharm. Co., Ltd | 2006-08-01 |
| Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder (NCT00373672) | Northwestern University | 2006-08-01 |
| Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia (NCT00361543) | The Alfred | 2006-08-01 |
| Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. (NCT00325689) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2006-07-01 |
| Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia (NCT00797277) | National Taiwan University Hospital | 2006-07-01 |
| An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. (NCT00391261) | Cambridge Health Alliance | 2006-07-01 |
| Cognitive Therapy for Negative Symptoms and Functioning (NCT00350883) | University of Pennsylvania | 2006-07-01 |
| A Definitive Estrogen Patch Study (ADEPT) (NCT00357006) | The Alfred | 2006-07-01 |
| Open-label Ziprasidone Study for Psychosis Treatment in Adolescents (NCT00421954) | New York State Psychiatric Institute | 2006-05-01 |
| Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia (NCT00337662) | Eli Lilly and Company | 2006-05-01 |
| Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (NCT00330863) | Northwell Health | 2006-05-01 |
| Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness (NCT00500695) | Rutgers, The State University of New Jersey | 2006-05-01 |
| Effects of Antipsychotic Medications on Energy Intake and Expenditure (NCT00836251) | Washington University School of Medicine | 2006-04-01 |
| Optimizing Response in Psychosis Study (NCT00314327) | Northwell Health | 2006-04-01 |
| Smoking Relapse Prevention in Schizophrenia (NCT00320697) | North Suffolk Mental Health Association | 2006-04-01 |
| Thinking Skills for Work in Severe Mental Illness (NCT01926613) | Dartmouth-Hitchcock Medical Center | 2006-04-01 |
| Trial of Cognitive Behavioral Therapy for Schizophrenia (NCT00300651) | Philipps University Marburg | 2006-03-01 |
| Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? (NCT00306475) | Northwestern University | 2006-03-01 |
| Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) (NCT00303602) | Eli Lilly and Company | 2006-03-01 |
| Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia (NCT00231335) | Emory University | 2006-03-01 |
| Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis (NCT00369239) | Janssen Pharmaceutica N.V., Belgium | 2006-03-01 |
| A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder (NCT00796081) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-01-01 |
| Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder (NCT00139919) | Solvay Pharmaceuticals | 2006-01-01 |
| A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine (NCT00791622) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-01-01 |
| Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome (NCT00288366) | Northwestern University | 2006-01-01 |
| Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging (NCT00288340) | Vanderbilt University | 2006-01-01 |
| Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes (NCT00288353) | Northwestern University | 2006-01-01 |
| Risperdal Consta and Health Care Utilization in Patients With Schizophrenia (NCT00313391) | Emory University | 2005-12-01 |
| Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation (NCT00167310) | University of Pittsburgh | 2005-09-01 |
| Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia (NCT00423943) | University of California, Los Angeles | 2005-09-01 |
| Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia (NCT00148083) | University of Illinois at Chicago | 2005-09-01 |
| An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia (NCT00269919) | Janssen Korea, Ltd., Korea | 2005-08-01 |
| Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine (NCT00312598) | University of North Carolina, Chapel Hill | 2005-08-01 |
| Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia (NCT00139906) | Solvay Pharmaceuticals | 2005-08-01 |
| Recovery Group Pilot (NCT00522613) | Kaiser Permanente | 2005-07-01 |
| AIMHI NT Relapse Prevention Trial (NCT00192582) | Menzies School of Health Research | 2005-07-01 |
| PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders (NCT00399334) | Janssen-Cilag, S.A. | 2005-06-01 |
| To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox (NCT00141479) | Solvay Pharmaceuticals | 2005-05-01 |
| Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics (NCT00458211) | Bronx Psychiatric Center | 2005-05-01 |
| Study of Amantadine for Weight Stabilization During Olanzapine Treatment (NCT00287352) | University of North Carolina, Chapel Hill | 2005-05-01 |
| The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia (NCT00373126) | North Suffolk Mental Health Association | 2005-04-01 |
| Abilify Therapy for Reducing Comorbid Substance Abuse (NCT00208169) | Creighton University | 2005-03-01 |
| Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia (NCT00434980) | Beth Israel Deaconess Medical Center | 2005-02-01 |
| Functional Rehabilitation of Older Patients With Schizophrenia (NCT00237796) | US Department of Veterans Affairs | 2005-02-01 |
| D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia (NCT00237848) | Yale University | 2005-02-01 |
| Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder (NCT01888107) | Janssen-Cilag S.p.A. | 2005-01-01 |
| High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder (NCT00297947) | Manhattan Psychiatric Center | 2004-12-01 |
| Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia (NCT00138775) | Sheba Medical Center | 2004-10-01 |
| A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis (NCT00246259) | Janssen-Ortho Inc., Canada | 2004-10-01 |
| A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder (NCT00645229) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-09-01 |
| Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) (NCT00212771) | Organon and Co | 2004-09-01 |
| Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) (NCT00517075) | New York State Psychiatric Institute | 2004-09-01 |
| Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder (NCT00090012) | Eli Lilly and Company | 2004-07-01 |
| Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) (NCT00304655) | Korea Otsuka Pharmaceutical Co., Ltd. | 2004-07-01 |
| The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning (NCT00566735) | Massachusetts General Hospital | 2004-07-01 |
| Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence (NCT00215579) | Duke University | 2004-04-01 |
| The Effects of Aripiprazole on Patients With Metabolic Syndrome (NCT00224822) | New Mexico VA Healthcare System | 2004-03-01 |
| Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder (NCT00156715) | Dartmouth-Hitchcock Medical Center | 2004-03-01 |
| Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder (NCT00095524) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-03-01 |
| Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety (NCT00177008) | University of Medicine and Dentistry of New Jersey | 2004-03-01 |
| L-carnosine for Schizophrenia (NCT00177177) | University of Pittsburgh | 2004-03-01 |
| Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia (NCT00283179) | Taiwan Otsuka Pharm. Co., Ltd | 2004-03-01 |
| Galantamine for Cognition in People With Schizophrenia (NCT00320736) | North Suffolk Mental Health Association | 2004-01-01 |
| Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? (NCT00206544) | The Alfred | 2004-01-01 |
| Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills (NCT00223418) | The University of Texas Health Science Center at San Antonio | 2004-01-01 |
| A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders (NCT00650611) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-12-01 |
| A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs (NCT00649064) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-12-01 |
| Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia (NCT00208143) | Creighton University | 2003-11-01 |
| A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia (NCT00222794) | University of Pittsburgh | 2003-11-01 |
| A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder (NCT00650429) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-10-01 |
| Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder (NCT00190749) | Eli Lilly and Company | 2003-10-01 |
| Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) (NCT00212784) | Organon and Co | 2003-09-04 |
| A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder (NCT00206102) | AstraZeneca | 2003-09-01 |
| Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder (NCT00395031) | Manhattan Psychiatric Center | 2003-09-01 |
| Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder (NCT00100776) | Eli Lilly and Company | 2003-09-01 |
| Cognitive Training for Patients With Schizophrenia (NCT01521026) | University of California, San Diego | 2003-09-01 |
| Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI) (NCT00211380) | Louisiana State University Health Sciences Center Shreveport | 2003-08-01 |
| As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations (NCT00796185) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-08-01 |
| Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS) (NCT00211302) | Louisiana State University Health Sciences Center Shreveport | 2003-08-01 |
| Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus (NCT00222807) | University of Pittsburgh | 2003-08-01 |
| Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin (NCT00177580) | University of Pittsburgh | 2003-07-01 |
| Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder (NCT00061802) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-06-01 |
| Effects of Modafinil on Brain Function in Patients With Schizophrenia (NCT00057707) | National Institute of Mental Health (NIMH) | 2003-03-26 |
| Cognitive Skills Training Using Computer for Patients With Severe Mental Illness (NCT01036282) | Nathan Kline Institute for Psychiatric Research | 2003-02-01 |
| Serotonin 1A Agonists and Cognition in Schizophrenia (NCT00178971) | Northwestern University | 2003-01-01 |
| Treatment of Schizophrenia Through Internet-Based Psychoeducation (NCT00051233) | University of Pittsburgh | 2003-01-01 |
| Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia (NCT00401089) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2002-12-01 |
| Improving Antipsychotic Adherence Among Patients With Serious Mental Illness (NCT00057135) | US Department of Veterans Affairs | 2002-11-01 |
| The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study (NCT00206557) | The Alfred | 2002-10-01 |
| A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937) (NCT01101464) | Organon and Co | 2002-10-01 |